Merck says Keytruda injection on par with approved IV version in trial
Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...
The Rebecca Foundation, in collaboration with Merck Foundation, has presented 30 brilliant but needy girls with school ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback